NCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
Clinical Trials
8 trialsNCT04439266 2025-11-19
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06357975 2025-10-31
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439253 2025-09-18
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05160922 2025-09-03
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03874273 2019-03-14
Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Unknown
NCT03085186 2017-08-29
Treatment With Crizotinib Single Patient Expanded Access IND 134375
University of Pittsburgh
No longer available